UY24375A1 - Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida - Google Patents

Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida

Info

Publication number
UY24375A1
UY24375A1 UY24375A UY24375A UY24375A1 UY 24375 A1 UY24375 A1 UY 24375A1 UY 24375 A UY24375 A UY 24375A UY 24375 A UY24375 A UY 24375A UY 24375 A1 UY24375 A1 UY 24375A1
Authority
UY
Uruguay
Prior art keywords
diseases
treatment
quinolin
procedure
preparation
Prior art date
Application number
UY24375A
Other languages
English (en)
Inventor
Carlo Farina Dr
Giuseppe Giardina Dr
Mario Grugni Mr
Luca Francesco Raveglia Mr
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI952462 external-priority patent/IT1276171B1/it
Priority claimed from IT96MI001688 external-priority patent/IT1307330B1/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Publication of UY24375A1 publication Critical patent/UY24375A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe un procedimiento para preparar un compuesto de fórmula (I) (figura 1) o una sal del mismo, o un solvato del mismo, en el cual, Ar es fenilo o naftilo; R2 es un resto -X-(CH2)n-Y en el que Y es un grupo heterocíclico de un solo anillo o de anillos condensados unido a N, opcionalmente sustituido, entre otras posibilidades. Como ejemplo no limitante: (S)-N-(alfa-etilbencil)-3-morfolinometil-2-fenilquinoleina-4-carboxamida. Son de uso potencial en la prevención y el tratamiento de condiciones clínicas que se caracterizan por la sobreestimulación de los receptores de taquiquinina, como por ejemplo enfermedades respiratorias como enfermedas pulmonar obstructiva crónica; enfermedades inflamatorias como osteoartritis, psoriasis y dolor inflamatorio; enfermedades oftálmicas como conjuntivitis; enfermedades cutáneas como ronchas, dermatitis de contacto; reacciones inmunológicas adversas como rechazo de tejidos transplantados y lupus eritematoso sistémico. Además son de uso particular en el tratamiento de trastornos del sistema nervioso central como ansiedad, depresión, psicosis y esquizofrenia; entre otros.
UY24375A 1995-11-24 1996-11-22 Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida UY24375A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI952462 IT1276171B1 (it) 1995-11-24 1995-11-24 Derivati chinolinici
IT96MI001688 IT1307330B1 (it) 1996-08-02 1996-08-02 Derivati chinolinici

Publications (1)

Publication Number Publication Date
UY24375A1 true UY24375A1 (es) 1997-05-22

Family

ID=26331327

Family Applications (2)

Application Number Title Priority Date Filing Date
UY24375A UY24375A1 (es) 1995-11-24 1996-11-22 Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida
UY24555A UY24555A1 (es) 1995-11-24 1997-05-16 Nuevos compuestos

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY24555A UY24555A1 (es) 1995-11-24 1997-05-16 Nuevos compuestos

Country Status (26)

Country Link
US (1) US20020068827A1 (es)
EP (1) EP1019377A1 (es)
JP (1) JP2000513325A (es)
KR (1) KR19990071598A (es)
CN (1) CN1207729A (es)
AP (1) AP9801238A0 (es)
AR (1) AR004735A1 (es)
AU (1) AU1031897A (es)
BG (1) BG102557A (es)
BR (1) BR9611757A (es)
CA (1) CA2238328A1 (es)
CZ (1) CZ158098A3 (es)
DZ (1) DZ2128A1 (es)
EA (1) EA001771B1 (es)
HU (1) HUP9901016A3 (es)
IL (1) IL124418A0 (es)
MA (1) MA24011A1 (es)
MX (1) MX9804108A (es)
NO (1) NO311213B1 (es)
OA (1) OA11011A (es)
PL (1) PL326928A1 (es)
SK (1) SK66898A3 (es)
TR (1) TR199800883T2 (es)
TW (1) TW409123B (es)
UY (2) UY24375A1 (es)
WO (1) WO1997019926A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041506A1 (en) * 1997-03-14 1998-09-24 Smithkline Beecham Corporation Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
HUP0002300A3 (en) * 1997-05-23 2002-01-28 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
US6339089B2 (en) * 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
US6262070B1 (en) 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
IL143137A0 (en) * 1998-11-20 2002-04-21 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
PT1394150E (pt) * 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
JP2002540206A (ja) * 1999-03-11 2002-11-26 ニューロゲン コーポレイション アリールの縮合した２，４−二置換ピリジン：ｎｋ３受容体リガンド
JP2002540203A (ja) 1999-03-29 2002-11-26 ニューロゲン コーポレイション Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
WO2002013825A1 (en) * 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
JP2004517062A (ja) * 2000-11-13 2004-06-10 グラクソスミスクライン・ソシエタ・ペル・アチオニ Ｎｋ−３およびｎｋ−２アンタゴニストとしてのキノリン誘導体
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
DE60209362T2 (de) * 2001-04-11 2006-10-26 Glaxosmithkline S.P.A. 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
MY134211A (en) * 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
CA2493854A1 (en) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US20070060593A1 (en) * 2003-06-25 2007-03-15 Kerns Jeffrey K 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
GB0318727D0 (en) * 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
US20080200500A1 (en) * 2005-06-03 2008-08-21 Astrazeneca Ab Quinoline Derivatives as Nk3 Antagonists
CA2613001A1 (en) * 2005-06-23 2006-12-28 Astrazeneca Ab Quinoline 3 -sulfonate esters as nk3 receptor modulators
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
JP2009504640A (ja) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Ｎｋ−３受容体の調節剤としてのアミドアルキルピリジルキノリン
EP1915363A1 (en) * 2005-08-11 2008-04-30 AstraZeneca AB Oxopyridyl quinoline amides as nk3 receptor modulators
CN101282961A (zh) * 2005-08-11 2008-10-08 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的烷基吡啶基喹啉
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
TW200804288A (en) 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
CA2680761A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
CN102924375B (zh) * 2012-06-21 2015-02-18 江苏恩华药业股份有限公司 Talnetant中间体及其制备方法和应用
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
WO2016037954A1 (de) 2014-09-09 2016-03-17 Bayer Pharma Aktiengesellschaft Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung
JP2018512404A (ja) 2015-03-18 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト 置換ｎ−ビシクロ−２−アリール−キノリン−４−カルボキサミドおよびその使用
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
CA3059273A1 (en) * 2017-04-10 2018-10-18 Bayer Aktiengesellschaft Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
ATE161530T1 (de) * 1992-09-04 1998-01-15 Takeda Chemical Industries Ltd Kondensierte heterozyklische verbindungen, deren herstellung und verwendung
ES2227769T3 (es) * 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina

Also Published As

Publication number Publication date
AR004735A1 (es) 1999-03-10
BG102557A (bg) 1999-03-31
DZ2128A1 (fr) 2002-10-26
OA11011A (en) 2003-03-06
EA199800538A1 (ru) 1998-12-24
NO311213B1 (no) 2001-10-29
MA24011A1 (fr) 1997-07-01
CA2238328A1 (en) 1997-06-05
US20020068827A1 (en) 2002-06-06
NO982333L (no) 1998-07-22
WO1997019926A1 (en) 1997-06-05
MX9804108A (es) 1998-09-30
BR9611757A (pt) 1999-04-06
HUP9901016A2 (hu) 2000-03-28
TW409123B (en) 2000-10-21
CN1207729A (zh) 1999-02-10
EP1019377A1 (en) 2000-07-19
IL124418A0 (en) 1998-12-06
PL326928A1 (en) 1998-11-09
NO982333D0 (no) 1998-05-22
HUP9901016A3 (en) 2002-01-28
EA001771B1 (ru) 2001-08-27
AU1031897A (en) 1997-06-19
AP9801238A0 (en) 1998-06-30
CZ158098A3 (cs) 1998-10-14
SK66898A3 (en) 1998-12-02
UY24555A1 (es) 2001-04-30
JP2000513325A (ja) 2000-10-10
KR19990071598A (ko) 1999-09-27
TR199800883T2 (xx) 2000-12-21

Similar Documents

Publication Publication Date Title
UY24375A1 (es) Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida
TWI450900B (zh) 橋聯雜環化合物及使用方法
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
MX2007012636A (es) Compuestos de espiro-oxindol y sus usos como agentes terapeuticos.
FR2658818B1 (fr) Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2013505945A (ja) ピリド［４，３−ｂ］インドールおよび使用方法
JP2013505946A (ja) ピリド［３，４−ｂ］インドールおよび使用方法
JP2013505948A (ja) 架橋複素環化合物およびその使用
JP2012525431A (ja) ピリド［４，３−ｂ］インドールおよびその使用方法
JP2008535916A (ja) スピロ複素環化合物および治療剤としてのその使用
KR100561049B1 (ko) 시냅스 반응을 향상시키기 위한 벤즈옥사진 화합물
CN109641898A (zh) 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
JP7492964B2 (ja) 神経網膜疾患の治療及び／又は予防において治療活性物質として使用する化合物
DE69533194T2 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
CN100400540C (zh) 作为抗抑郁药的异唑啉衍生物
DE69006452T2 (de) Derivate und Analoge von Pyrimidon zur Behandlung von Asthma und bestimmte Hautkrankheiten.
JPH072831A (ja) ベータ−３選択性アドレナリン作動剤としてのアミノシクロアルカノベンゾジオキソール類
BR112019025866A2 (pt) compostos e composições para indução de condrogênese
JP2006506355A (ja) β−ヒドロキシフェニルアルキルアミンおよびその緑内障治療への使用
AU2002250983B2 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
AR036092A1 (es) Un derivado de benzoxazepina, su uso y una composicion farmaceutica que lo comprende
CN117337289A (zh) 用于治疗脑病症的四环化合物
JP4781362B2 (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
TW378209B (en) Benzo[g]quinoline derivatives, their preparation and the pharmaceutical composition containing them

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20161122